GSK said Arexvy, its vaccine for respiratory syncytial virus (RSV) showed positive preliminary results in a late-stage trial to protect adults aged 50 to...
China's largest vaccines company Zhifei will pay British drugmaker GSK 2.5 billion pounds ($3.05 billion pound) for the exclusive rights to distribute GSK's shingles...
GSK and Novartis on Thursday reinforced commitments to address neglected tropical diseases, as world leaders and health experts gather in Rwanda to discuss ways...
Unilever faces a dilemma after its 50 billion pound ($68 billion) offer for GlaxoSmithKline's consumer healthcare assets was rejected -- should it raise the...
British drugmaker GSK said on Tuesday its antibody-based COVID-19 therapy with U.S. partner Vir Biotechnology is effective against all mutations of the new Omicron...
GlaxoSmithKline and CureVac said a study on macaque monkeys showed their jointly-developed mRNA COVID-19 vaccine candidate to be "strongly improved" in protecting against the...
GSK said on Friday its anaemia drug for patients with kidney disease succeeded in late-stage trials, marking an important milestone for the British drugmaker...
Sanofi and GlaxoSmithKline have received an approval from Indian authorities for a late-stage clinical trial of their protein-based COVID-19 vaccine candidate, the drugmakers said...
The companies reported positive results from interim human trials earlier this month after a disappointing outcome from initial studies last year left France without its own vaccine
GSK and CureVac, backed by Microsoft billionaire Bill Gates, will work on developing up to five so-called mRNA-based vaccines and monoclonal antibodies (mAbs) for infectious diseases
Britain is close to a 500 million pound ($624 million) supply deal with Sanofi and GlaxoSmithKline for 60 million doses of a potential COVID-19 vaccine.
There is a notable name missing from the frontrunners in the race to test experimental immunisations against the novel coronavirus: the world’s largest vaccine maker GlaxoSmithKline
The world’s largest vaccine maker said it was in talks with governments to back a manufacturing expansion that would help to scale up production of future vaccines for COVID-19
While Ebola is a deadly and contagious disease, it is also still relatively rare, making the potential market for a vaccine sporadic and very likely unprofitable
LONDON: Pharmaceutical giants GlaxoSmithKline and Pfizer on Wednesday announced a merger of their consumer healthcare units that produce over-the-counter medicines.
GSK said it would have...
LONDON: GlaxoSmithKline notched up a second win for its pioneering "real world" approach to testing new drugs on Friday as its inhaled medicine Breo...
SEATTLE: Gilead Sciences has thrown down a challenge to GlaxoSmithKline with good clinical trial results for an experimental HIV drug that works in the...